Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

7.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

667
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
667
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

7.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

959
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
959
Structure and Function of Platelets01:18

Structure and Function of Platelets

1.8K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.8K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

2.9K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelial cannabinoid CB1 receptor deficiency reduces shear stress-induced arterial inflammation and lipid uptake.

Nature communications·2026
Same author

Review Article: Implementation Challenges in Helicobacter pylori Management: Bridging Evidence and Real-World Practice.

Alimentary pharmacology & therapeutics·2026
Same author

Deletion of endothelial SOX9 reverses aging-induced cardiac dysfunction.

Cardiovascular research·2026
Same author

miRNA-26b Is Associated with Increased Connexin-40 Expression in Endothelial Cells Under Flow Conditions.

International journal of molecular sciences·2026
Same author

Elucidating the Pathogenic Role of Helicobacter pylori Infection in Hematologic Disorders: Mechanistic Insights and Future Perspectives.

Helicobacter·2026
Same author

CCR2<sup>+</sup> Neutrophils Exhibit a Proinflammatory Phenotype and Contribute to Plaque Vulnerability.

Arteriosclerosis, thrombosis, and vascular biology·2026

Related Experiment Video

Updated: Sep 29, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.1K

Targeting platelet-derived CXCL12 impedes arterial thrombosis.

Julian Leberzammer1,2, Stijn M Agten3, Xavier Blanchet1

  • 1Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.

Blood
|March 21, 2022
PubMed
Summary
This summary is machine-generated.

Targeting platelet-derived CXCL12 via CXCR4 inhibition with the peptide i[VREY]4 offers a novel therapeutic strategy for arterial thrombosis. This approach reduces platelet aggregation and thrombus formation without increasing bleeding risk, unlike current therapies.

More Related Videos

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

15.9K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.9K

Related Experiment Videos

Last Updated: Sep 29, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.1K
Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice
11:18

Real-time Imaging of Heterotypic Platelet-neutrophil Interactions on the Activated Endothelium During Vascular Inflammation and Thrombus Formation in Live Mice

Published on: April 2, 2013

15.9K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.9K

Area of Science:

  • Cardiovascular Biology
  • Thrombosis Research
  • Drug Discovery

Background:

  • Arterial thrombosis presents significant clinical challenges, necessitating novel therapeutic targets.
  • Understanding molecular mechanisms of platelet aggregation is crucial for developing improved treatments.
  • Chemokine CXCL12 and its receptor CXCR4 play a role in platelet activation.

Purpose of the Study:

  • To investigate the role of platelet-derived CXCL12 in arterial thrombosis.
  • To evaluate the therapeutic potential of inhibiting the CXCL12-CXCR4 axis.
  • To explore novel peptide-based inhibitors for atherothrombosis.

Main Methods:

  • Inhibition of CXCR4 using specific antagonists.
  • Assessment of platelet aggregation under static and arterial flow conditions.
  • Evaluation of arterial thrombosis and neointimal lesion formation in mouse models.
  • Mechanistic studies involving Bruton's tyrosine kinase (Btk) and integrin signaling.
  • Development and testing of a novel peptide inhibitor, i[VREY]4.

Main Results:

  • CXCR4 inhibition attenuated collagen- and plaque homogenate-induced platelet aggregation.
  • Platelet-specific CXCL12 deficiency reduced arterial thrombosis and neointimal hyperplasia without affecting bleeding time.
  • CXCL12-CXCR4 signaling activates Btk, leading to integrin αIIbβ3 activation and platelet aggregation.
  • The peptide i[VREY]4 inhibited Btk activation and platelet aggregation, preventing thrombosis.
  • i[VREY]4 did not prolong in vitro bleeding time, unlike standard antiplatelet drugs.

Conclusions:

  • Platelet-derived CXCL12 contributes to arterial thrombosis.
  • Targeting the CXCL12-CXCR4-Btk axis is a promising strategy for treating atherothrombosis.
  • The peptide i[VREY]4 demonstrates therapeutic potential as a novel antiplatelet agent with an improved safety profile.